ZWZhiyu Wang

Zhiyu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiyu Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Hong

    Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China

    4 shared publications
  • Yaning Wei

    Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China

    4 shared publications
  • Shenyong Su

    Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China

    3 shared publications
  • Kunjie Wang

    Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China

    2 shared publications
  • Lin An

    Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China

    2 shared publications
  • Aimin Zang

    Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Metastatic Laryngeal Minor Salivary Gland Carcinoma to the Liver: Successful Treatment with Anti-EGFR-Based Combination Therapy - A Case Report and Literature Review

    by Zhigui Guo, Qianwen Li, Dan Hong, Yaning Wei, Zhiyu Wang

    Laryngeal minor salivary gland carcinoma is a rare malignancy, accounting for less than 1% of laryngeal cancers. We present a case of a 43-year-old male with a history of surgically resected laryngeal ductal carcinoma who developed liver metastases. Initial pathology from the liver lesion was inconclusive, leading to a misdiagnosis of intrahepatic cholangiocarcinoma. After progression on first-line chemotherapy and immunotherapy, the diagnosis was revised to metastatic laryngeal minor salivary gland carcinoma, supported by positive EGFR expression. Second-line treatment with the anti-EGFR agent cetuximab, combined with immunotherapy and chemotherapy (sindilizumab, albumin-bound paclitaxel, and S-1), resulted in a sustained partial response. This case highlights the diagnostic challenges of this rare tumor and suggests the potential efficacy of anti-EGFR therapy in EGFR-expressing metastatic laryngeal salivary gland carcinoma. Given the rarity and aggressive nature of primary laryngeal salivary duct carcinoma, it remains a significant challenge for both diagnosis and treatment. The current case underscores the difficulty in identifying the primary tumor site, especially when metastasis occurs. Additionally, the effectiveness of anti-EGFR therapy in EGFR-expressing tumors offers a promising treatment avenue. Further research is essential to establish standardized treatment protocols, identify predictive biomarkers, and optimize combination strategies for this uncommon malignancy.


  • Open Access

    Differential response to immunotherapy in different lesions of MSI-H double primary colorectal cancer: a case report and literature review

    by Zhigui Guo, Dan Hong, Yaning Wei, Yue Huo, Shenyong Su, Yan Shi, Lin An, Kunjie Wang, Yajing Su, Zhiyu Wang

    Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC). In the KEYNOTE-177 trial, for individuals with advanced CRC exhibiting MSI-H or mismatch repair deficiency (dMMR), treatment with pembrolizumab as a single agent demonstrated a superior outcome compared to standard systemic chemotherapy. The study revealed a notably higher objective response rate (43.8% versus 33.1%) and an extended progression-free survival duration (16.5 versus 8.2 months). These findings imply that pembrolizumab may be regarded as a front-line treatment option for patients with advanced CRC who have MSI-H/dMMR status. Case Description: The patient with double primary CRC, both of which were identified as MSI-H through next generation sequencing (NGS). Following a regimen of immunotherapy-based combination therapy, the rectal lesion achieved a complete clinical response (cCR), while the colon lesion displayed continued progression, indicating primary resistance to treatment. Conclusions: Specific histological subtypes of CRC, such as mucinous adenocarcinoma, might adversely affect the efficacy of immunotherapy, resulting in primary treatment resistance. Consequently, in the case of this particular cancer subtype, local surgical resection may be a more appropriate treatment strategy.


  • Open Access

    Case Report: A management strategy and clinical analysis of primary squamous cell carcinoma of the colon

    by Xiang Wu, Shenyong Su, Yaning Wei, Dan Hong, Zhiyu Wang

    Primary colorectal squamous cell carcinoma (CSCC) is a rare pathological subtype. Currently, clinical data with regards to its prognosis and treatment is limited, and there is no optimal treatment method. The case presented involves a proficient mismatch repair (pMMR) and microsatellite-stable (MSS) Colorectal cancer (CRC) patient with squamous cell carcinoma (SCC) located transversely in the colon. Based on the imaging assessment, the tumor infiltration depth is classified as T4. After receiving 4 cycles of neoadjuvant treatment with oxaliplatin and capecitabine (XELOX), the patients were evaluated for partial response (PR) in 2 cycles and stable disease (SD) in 4 cycles. The patient underwent a right hemicolectomy and received postoperative paclitaxel/cisplatin (TC) adjuvant chemotherapy. After 23 months, a systemic examination revealed abdominal metastasis. A needle biopsy was conducted on the detected abdominal metastases, with the resulting pathology indicating the presence of metastatic SCC. The individual exhibited expression of programmed cell death ligand 1 (PD-L1) and a mutation in the TP53 gene. Considering the patient’s disease recurrence based on medical history, a treatment plan was formulated. This involved Sintilimab plus Cetuximab and the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen. The patient received four cycles of treatment with an efficacy evaluation of SD- and seven cycles of treatment with an efficacy evaluation of SD+, which resulted in a progression-free survival (PFS) duration of 7 months. This case study presents the conventional XELOX chemotherapy protocol, which has shown limited effectiveness, and highlights the favorable results achieved by implementing the TC adjuvant chemotherapy regimen in individuals diagnosed with primary colonic SCC. Furthermore, combining immune checkpoint blockade (ICB) with other therapies for patients with advanced disease is anticipated to provide an extended duration of survival.


  • Open Access

    A HER2-mutant patient with late-stage duodenal adenocarcinoma benefited from anti-HER2 therapy and PD-1 inhibition: a case report

    by Zhiyu Wang, Wenwen Li, Yaning Wei, Lin An, Shenyong Su, Chenglin Xi, Kunjie Wang, Dan Hong, Yan Shi

    Duodenal adenocarcinoma (DA) is a subtype of small bowel adenocarcinoma (SBA). Compared with gastrointestinal cancers such as colorectal cancer and gastric cancer, SBA is less common. For patients with advanced and metastatic DA, chemotherapies are usually extrapolated from colorectal cancer and gastric cancer but the therapeutic effects remain undefined. Herein, we reported a 50-year-old female patient whom was diagnosed as stage IV DA with metastasis to both lungs and retroperitoneal lymph nodes. The next generation sequencing (NGS) using a panel consisting of 168 cancer related genes revealed amplification of the HER2/ERBB2 gene which has been a well-recognized therapeutic target among various tumor types. The anti-HER2 targeted therapy trastuzumab was used in combination with XELOX (oxaliplatin and capecitabine) as the first line treatment. The patient achieved partial response (PR) and had progression-free survival (PFS) of six months. After progressive disease (PD), the patient started the second line treatment with trastuzumab and PD1 inhibitors and remained stable disease (SD) with PFS for three months. The use of trastuzumab in neoadjuvant and adjuvant settings have been reported in sporadic cases. To the best of our knowledge, it is the first report to use anti-HER2 therapy and PD-1 inhibition as systemic therapy for advanced DA patients.


  • Open Access

    Inducible T-cell co-stimulators regulate the proliferation and invasion of human hepatocellular carcinoma HepG2 cells

    by Yaning Wei, Yanan Wang, Aimin Zang, Yanhong Shang, Zizheng Song, Zhiyu Wang, Yangyang Wang, Hua Yang

    This study determined the regulatory effects of inducible T-cell co-stimulators (ICOS) in human hepatocellular carcinoma HepG2 cells using a RNA interference (RNAi) technique. A RNAi technique was used to knockdown the expression of ICOS. ICOS expression after knockdown was detected as mRNA and protein levels by RT-PCR and Western blot, respectively. A MTT colorimetric assay was used to detect cell proliferation, and the Transwell assay was used to detect cell invasion. Western blot was carried out to detect the level of Bcl-2, AKT, and PI3K protein expression in different groups. The proliferation of HepG2 cells were significantly decreased after ICOS siRNA transfection (EG group). Similarly, the results of the Transwell experiment showed that invasion of HepG2 cells in the EG group was clearly reduced compared to the negative control (NC) and blank control groups (CON). Western blot analysis showed that knockdown of ICOS expression reduced the levels of Bcl-2 and AKT, and also significantly up-regulated the level of PI3K phosphorylation (P < 0.01). Down-regulating ICOS expression in HepG2 cells suppressed cell proliferation and invasion. The underlying mechanism may be related to the expression of the downstream factor, PI3K/AKT.